#### Special Issues

Special Issue Title: Gynecological Tumors

· Deadline for manuscript submissions: 31 December 2021

Special Issue Editor

Guest Editor

 Dr. Michail Varras Obstetrics and Gynecology Department, “Elena Venizelou” General Maternity State Hospital, Greece

Interests: Gynecological oncology; minimally invasive gynecology; laparoscopy; hysteroscopy; reproductive medicine; fetal medicine

Special Issue Information

Dear Colleagues,

The pathogenesis of cancer is a complex process, whose occurence and development involve multiple pathways and numerous genetic alterations such as gene mutations, amplifications and chromosomal translocations or rearrangements. Gynecological malignant tumors exibit very heterogeneity including various histological types with different molecular characteristics, genetic risk factors and clinical behaviors. Inhibition of the oncogenic pathways is currently under clinical trials for the therapy of gynecological malignant tumors. Detection of several molecular biomarkers in the tumors of the female genital tract could provide more information about the underlying mechanisms of cancer proliferation, invasion, persistance, metastasization and recurrence. Ovarian carcinoma is one of the deadly causes of gynecological cancer worldwide because the disease in advanced-stage consistently relapse despite surgical resection and chemotherapy combination. In patients with endometrial carcinoma, the clinicians should take into consideration multiple factors, which may affect therapeutic options in order to determine the appropriate therapeutic regimens to avoid over- or under–treatment. Various tumor-suppressor genes, oncogenes and tumor growth factors apart from high-risk HPV infection are involved in cervical carcinogenesis. The prognosis of patients with advanced stage cervical carcinoma remains poor despite treatment schedules with combination of radiotherapy and chemotherapy. Actually, one of the causes of cervical cancer relapse is the high levels of radiation during radiotherapy. Therefore there is an urgent need to discover and identify several anticancer potential molecules for development of effective novel targeted therapies in order to suppress cell growth and metastasis of gynecological malignant tumors.

The goal of this special issue is to discover further the mechanisms of tumorogenesis in human uterus, ovaries, fallopian tubes, vulva and vagina on cell proliferation, survival and failure to undergo an appropriate apoptosis. Also, the aim of this special issue is to publish both original articles and comprehensive reviews about the potential association between the expression of molecular tumor biomarkers and the clinicopathological characteristics of patients with gynecological malignant tumors, their treatment options and prognosis. Furthermore, this special issue will address the environmental, genetic and cellular mechanisms of common benign gynecological tumors including uterine leiomyomas and endometriomas and the specific gene therapy protocols, especially for women who want to preserve their fertility.

Dr. Michail Varras, M.D., M.Sc., Ph.D.

Consultant Obstetrician-Gynecologist

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at https://ceog.imrpress.org by registering and logging in to this website. Once you are registeredclick here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the page. Clinical and Experimental Obstetrics & Gynecology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit thepage before submitting a manuscript. The for publication in this open access journal is $1250. We normally offer a discount about 30% (APC:$850) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Keywords

Gynecological tumor; benign; malignant; uterine leiomyoma; endometrioma; oncogene; tumor suppressor gene; biomarker; cell apoptosis; expression; signaling; treatment; gene therapy; clinicopathological analysis; prognosis; resistance; survival

Planned Paper

Type: Review
Title: Endometrial carcinomas: Genomic-based pathways to tumorigenesis and biological tissue biomarkers with potential prognostic and clinical significance
Authors: Dr. Michail Varras

Type: Review
Title: Prognostic significance of molecular alterations in ovarian carcinomas
Authors: Dr. Michail Varras

Type: Review
Title: Molecular tumorigenesis, tissue biomarkers and clinical characteristics of human cervical carcinomas: Implications for diagnosis, personalized therapeutic strategies, prognosis and future potential
Authors: Dr. Michail Varras